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Objective: Cervical cancer is a leading cause of cancer mortality in South Africa. How-
ever, little is known about oral human papillomavirus (HPV) infection in high human
immunodeficiency virus (HIV) seroprevalence settings.
Method:Thirty-four adult heterosexual couples attending an HIV testing center in Soweto,
South Africa were enrolled. Each participant provided an oral rinse sample and genital swab,
which were tested for 37 types of HPV DNA, and completed a risk behavior survey.
Results: Median age was 31 years and 9% (3/34) of men and 29% (10/34) of women
enrolled tested HIV-positive; median CD4 count was 437 cells/mm3. Oral HPV prevalence
was similar in women and men (12 vs. 18%, p=0.48), and was non-significantly higher
in HIV-infected vs. HIV-uninfected (23 vs. 13%, p=0.34) subjects. Most men (82%) and
women (84%) reported ever performing oral sex. Median number of lifetime sexual part-
ners was “2–5” while median number of lifetime oral sex partners was 1. Oncogenic HPV
subtypes were detected in 4% of oral, 26% of penile, and 74% of vaginal samples, includ-
ing HPV16 in 1, 12, and 21% of these samples respectively. Genital HPV prevalence was
significantly higher than oral HPV prevalence (75 vs. 15%, p≤0.001).Thirty-five percent of
couples (12/34) had at least one type-specific concordant vaginal-penile HPV infection but
only one of nine couples with oral HPV had concordant oral–oral infection. However, 67%
(4/6) of men and 25% (1/4) of women with oral HPV infection had partners with concordant
genital HPV infection.
Implications and Impact: Oral–oral HPV concordance between couples is low, but oral-
genital and genital–genital HPV concordance is higher, including concordance of male oral
HPV infection with their partners’ vaginal HPV infection.This data is consistent with possi-
ble transmission of vaginal HPV infection to the oral cavity of sexual partners performing
oral sex.
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INTRODUCTION
Human papillomavirus (HPV) is a sexually transmitted infection
that causes squamous cervical cancer and some vaginal and anal
cancers (1, 2). More recent data shows that HPV also causes a
subset of head and neck cancers including 50–75% of oropha-
ryngeal cancers (3). While initial cross-sectional studies from the
United States suggest that oral HPV prevalence is elevated among
human immunodeficiency virus (HIV)-infected individuals and
further increased with immunosuppression (4, 5), there is cur-
rently limited information about oral HPV infections in Africa.
Yet the incidence of oral cancer in South Africa is 2.7 per 100,000
per year and the incidence of pharyngeal cancer is 2.4 per 100,000
per year (6).
In South Africa, HIV prevalence is estimated at 17.3%, and
5.6 million people are living with HIV as of 2011 (7). Since the
advent of effective antiretroviral therapy (ART) and its roll-out
in Sub-Saharan Africa, HIV-infected patients are living longer.
With this increase in survival comes an increased opportunity
for progression of oncogenic viral infections into malignancies,
including increased incidence of HPV-associated oral, genital, and
anal cancers (8, 9).
Cervical HPV infection has been well studied in South Africa,
where cervical cancer is one of the leading causes of cancer mor-
tality in women (10). The prevalence of cervical HPV infection
approaches 80% among HIV-infected women (11) in whom high
rates of cervical premalignant lesions have been reported (12), an
effect apparently mitigated by ART (13). Owing to limited data
on oral HPV, the concordance of oral-cervical HPV infection has
not been well studied. Previous cross-sectional data from the U.S.
suggests that the risk factors such as tobacco use, immunosuppres-
sion, and increasing age might also be risk factors for persistent
oral HPV infection (5, 14).
www.frontiersin.org December 2013 | Volume 3 | Article 303 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vogt et al. Oral-genital HPV: evidence for transmission
We therefore evaluated oral and genital HPV prevalence, risk
factors and concordance among couples attending the Peri-
natal HIV Research Unit at Chris Baragwanath Hospital in
Johannesburg, South Africa.
MATERIALS AND METHODS
STUDY POPULATION
In 2011 we recruited 38 couples attending the Zazi Center at
the Perinatal HIV Research Unit, Chris Baragwanath Hospital in
Soweto, South Africa for HIV testing. The Zazi Center provides
free, walk-in, voluntary HIV counseling and testing for individ-
uals and couples. Clients who test positive for HIV receive CD4
count testing to assist in appropriate referral to care. To be included
in this study, participants were required to be 18 years or older and
be able to read English. A convenience sample that included all
couples coming to the Zazi HIV testing clinic during the enroll-
ment period were asked by their HIV testing counselor if they
were interested in participating in the study. Roughly 33% of the
individuals who came to the HIV clinic during this time period
came without a partner and were therefore not eligible for this
study. Sexually active couples who reported being together for at
least 1 month were eligible for enrollment as long as both partners
were willing to participate and provide informed consent. All 38
couples referred to the study coordinator enrolled in the study.
A couple was defined as two individuals (regardless of gender)
who self-identified as current sexual partners. Exclusion criteria
included an inability to provide consent, or an unwillingness to
provide an oral rinse sample and survey data. Individuals could
opt out of providing a genital sample. The study was approved
by the Johns Hopkins Bloomberg School of Public Health institu-
tional review board and the University of Witwatersrand human
research ethics committee.
Each study subject provided an oral rinse and gargle sam-
ple, a genital swab and completed a risk behavior survey. Oral
rinse and gargle specimens were obtained by having a partici-
pant gargle 10 ml of Scope mouthwash for a total of 30 s (10 s
rinse, 5 s gargle, 10 s rinse, 5 s gargle). Specimens were collected
in a sterile cup and stored at 4°C while awaiting transport to the
laboratory. Women were asked to provide a self-collected vagi-
nal sample, obtained using a Dacron applicator (Qiagen female
swab specimen collection kit) and stored at room temperature
while awaiting transport to the laboratory. The penile swab was
collected from participating men by a clinical study team mem-
ber and penile cells were collected using two Dacron HC (Qiagen)
swabs. One swab sampled the coronal sulcus and glans penis, while
the other sampled the penile shaft. Both were combined into one
collection vial and stored at room temperature (15). Initial pro-
cessing was performed in South Africa including centrifugation
at 2000 rpm at 4°C for 10 min, 2 ml supernatant saved, followed
by re-suspension of the pellet in 10 ml PBS and centrifuged at
2000 rpm at 4°C for 10 min and pellet re-suspended in 3 ml PBS
and split into two aliquots. All samples were stored locally at
−80°C until shipment to Baltimore lab for DNA purification,
amplification and HPV DNA detected by line blot hybridiza-
tion, as previously described (16, 17). Samples were tested for
37 types of HPV DNA; oncogenic HPV subtypes were defined as
16/18/31/33/35/39/45/51/52/56/58/59/68/73/82 (18–20).
All study participants were asked to complete a self-
administered risk factor questionnaire. Individuals from the same
couple were asked to fill out the survey in separate rooms to ensure
privacy of responses. The questionnaire included questions about
risk factors for oral HPV infection including demographics, recent,
and lifetime sexual behavior including performing oral sex, alco-
hol, tobacco, and drug use. Ever regular tobacco use was asked
as: “Have you ever smoked cigarettes regularly?” with response
options of: yes/no. Ever regular alcohol use was asked similarly.
Responses to many of the survey questions were categorical, such
as number of oral sexual partners, which was asked as: “In your
lifetime, how many different people have you performed oral sex
on?” with response options of: 0, 1, 2–5, 6–10,>10.
All study participants were tested for HIV as part of their clin-
ical care and if HIV-positive CD4 cell count by the Zazi clinic as
part of their clinical visit. Women with oncogenic vaginal HPV
infection were referred for Pap smears.
STATISTICAL ANALYSIS
Characteristics of participants were compared by gender and by
HIV status using chi-squared for categorical and test of medi-
ans for continuous variables. Chi-squared was used to compare
oral and genital HPV prevalence by HIV-status. Fischers exact test
was used is comparisons of any group with five or fewer sub-
jects. McNemar’s test was used to compare oral and genital HPV
prevalence among the paired male and female couples. Agreement
in HPV infections between partners was considered separately by
site (oral–oral, genital-oral, and genital–genital) and was described
as the proportion of couples who had one or more type-specific
concordant infections overall and when limited to subgroups who
had one type of infection present. All statistical analyses were per-
formed using STATA version 11.0 (College Station, TX, USA).
There were 4/38 couples recruited in which one of the partners
opted out of providing a genital sample; therefore all analyses
were restricted to the 34 couples with complete oral and genital
HPV data. Results were similar when these individuals were not
excluded (results not shown).
RESULTS
This pilot study included 13 individuals who tested positive for
HIV infection, as well as 55 people testing HIV-negative, called
HIV-uninfected (Table 1). HIV concordance was seen in 2 cou-
ples, 9 couples were HIV discordant, and 23 couples were HIV-
uninfected. The median CD4 count among HIV-positive indi-
viduals was 437 cells/mm3 [Interquartile range (IQR): 161–575
cells/mm3]. Median age was 31 years (IQR: 28–36). Women were
more likely than men to test HIV positive (29 vs. 9%, p= 0.03) and
women were significantly younger and less likely to use tobacco
or alcohol than men in the study (Table 1). Most men 27/33
(82%) and women 26/31 (84%) reported ever performing oral
sex. Median number of lifetime sexual partners was 2–5 (IQR: 2–
5, 6–10), while median number of lifetime oral sex partners was 1
(IQR: 1, 2–5).
HPV PREVALENCE
There were a total of 35 different genital HPV types detected
amongst the study participants, including HPV 16 and 62 (preva-
lence each 16.2%), 45 and 52 (each 11.8%), 61 (10.3%), 66 (8.8%),
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Table 1 | Characteristics of 34 couples attending Zazi Clinic for HIV counseling and testing, stratified by gender.
All (N =68) Female (N =34) Male (N =34) p-Value*
N (%)
Age in years(IQR) 31 (28–36) 30 (24–32.5) 33 (29–37) 0.021
HIV-STATUS
HIV-uninfected 55 (80.9) 24 (70.6) 31 (91.2) 0.031
HIV-infected 13 (19.1) 10 (29.4) 3 (8.8)
Median CD4 cell count among HIV+ (IQR)a 437 (161–575) 460 (272–566) 76 (9–584) 0.307
EVER REGULARTOBACCO USE
No 45 (66.2) 28 (82.4) 17 (50.0) 0.001
Yes 21 (30.9) 4 (11.8) 17 (50.0)
Unknown 2 (2.9) 2 (5.9)
EVER REGULAR ALCOHOL USE
No 29 (42.7) 18 (52.9) 11 (32.4) 0.039
Yes 31 (45.6) 11 (32.4) 20 (58.8)
Unknown 8 (11.8) 5 (14.7) 3(8.8)
EVER PERFORMED ORAL SEX?
No 11 (16.2) 5 (14.7) 6 (17.6) 0.828
Yes 53 (77.9) 26 (76.5) 27 (79.4)
Unknown 4 (5.9) 3 (8.8) 1 (2.9)
AGE FIRSTTIME PERFORMED ORAL SEX
<21 27 (39.7) 15 (44.1) 12 (35.3) 0.653
21–30 22 (32.4) 10 (29.4) 12 (35.3)
>30 4 (5.9) 1 (2.9) 3 (8.8)
Never 9 (13.2) 5 (14.7) 4 (11.8)
Unknown 6 (8.8) 3 (8.8) 3 (8.8)
NUMBER OF PARTNERS PERFORMED ORAL SEX ON IN LIFETIME
None 11 (16.2) 6 (17.6) 5 (14.7) 0.956
1 21 (30.9) 10 (29.4) 11 (32.4)
2–5 26 (38.2) 13 (38.2) 13 (38.2)
6–10 5 (7.4) 2 (5.9) 3 (8.8)
Unknown 5 (7.4) 3 (8.8) 2 (5.9)
NUMBER OF VAGINAL SEX PARTNERS IN LIFETIME
None 1 (1.5) 1 (2.9) 0 (0.0) 0.308
1 5 (7.4) 4 (11.8) 1 (2.9)
2–5 29 (42.7) 17 (50.0) 12 (35.3)
6–10 9 (13.2) 3 (8.8) 6 (17.7)
11–15 7 (10.3) 2 (5.9) 5 (14.7)
16–24 3 (4.4) 2 (5.9) 1 (2.9)
≥25 1 (1.5) 0 (0.0) 1 (2.9)
Unknown 13 (19.1) 5 (14.7) 8 (23.5)
*pValues were calculated using the Mann–Whitney test for continuous variables and chi-squared for all remaining variables and excluded those with unknown values.
aCD4 cell counts were available for only 11 of the HIV-infected individuals; this included 8 females and 3 males.
6, 18, 35, 72, 84, 89 (each 7.4%) as the most common types. For
oral HPV the most common infections detected were HPV 62
(prevalence 7.4%), 72 (5.9%), 35, 52, 33, 58 (each 2.9%), and 16,
74, 66 (each 1.5%).
Oral HPV prevalence was significantly lower than genital HPV
prevalence (15 vs. 75%, p≤ 0.001) (Table 2) but oral HPV preva-
lence was similar in women and men (12 vs. 18%, p= 0.48), and
was higher, but not statistically different, among HIV-infected
vs. HIV-uninfected individuals (23 vs.13%, p= 0.34). Genital
HPV prevalence was significantly higher in women vs. men
(91 vs. 59%, p= 0.005) and HIV-infected vs. HIV-uninfected
(100 vs. 69%, p= 0.02). Oncogenic HPV subtypes were detected
in 4% of oral, 29% of penile, and 74% of cervical sam-
ples, including HPV 16 in 1, 12, and 21% of these samples
respectively.
Comparing HIV-infected vs. HIV-uninfected individuals, HIV-
infected individuals displayed a statistically significantly higher
prevalence of both genital oncogenic HPV subtypes (76.9 vs.
45.5%, p= 0.04) and multiple HPV infections (84.6 vs. 29.1%,
p≤ 0.0001). For oral samples, there was a trend for higher
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Table 2 | Oral and Genital HPV Prevalence by gender and HIV status.
N (%)
Female
(N =34)
Male
(N =34)
p-Value* HIV-infected
(N =13)
HIV-uninfected
(N =55)
p-Value**
ORAL HPV
Any 4 (11.8) 6 (17.7) 0.48 3 (23.1) 7 (12.7) 0.34
Any oncogenic subtype (16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 68, 73, 82)
1 (2.9) 2 (5.9) 0.56 1 (7.7) 2 (3.6) 0.52
Any vaccine subtype (6, 11, 16, 18) 0 (0) 1 (2.9) 0.32 0 (0) 1 (1.8) 0.62
HPV 16 0 (0) 1 (2.9) 0.32 0 (0) 1 (1.8) 0.62
Multiple subtypes 2 (5.9) 4 (11.8) 0.41 2 (15.4) 4 (7.3) 0.35
GENITAL HPV
Any 31 (91.2) 20 (58.8) 0.005 13 (100.0) 38 (69.1) 0.02
Any oncogenic subtype (16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 68, 73, 82)
25 (73.5) 10 (29.4) 0.0001 10 (76.9) 25 (45.5) 0.04
Any vaccine subtype (6, 11, 16, 18) 13 (38.2) 6 (17.65) 0.02 9 (69.2) 10 (18.2) <0.0001
HPV 16 7 (20.6) 4 (11.8) 0.18 4 (30.8) 7 (12.7) 0.11
Multiple subtypes 20 (58.8) 7 (20.6) 0.0003 11 (84.6) 16 (29.1) <0.0001
*p Values comparing male and female partners were calculated using McNemar’s test for the comparison between couples.
**p Values comparing HIV+ and HIV− subjects were calculated using Chi-squared for the comparison between HIV+ and HIV− individuals.
oncogenic HPV prevalence (7.7 vs. 3.6%, p= 0.52) and multi-
ple HPV infections (15.4 vs. 7.3%, p= 0.35) in HIV-infected vs.
HIV-uninfected individuals, but this finding was not statistically
significant.
CONCORDANT HPV INFECTION
Concordant type-specific oral-genital HPV infection was detected
in 4/34 (12%) couples (Figure 1). In 3 (75%) of these four cou-
ples the partner with oral HPV reported ever performing oral sex.
Among the four couples with concordant oral-genital HPV infec-
tion, two couples had concordant HPV 62 infection, one couple
had concordant HPV 16 infection, and one couple had multiple
concordant subtypes (HPV 33/35/58) (Table 3). There were nine
couples where at least one individual had an oral HPV infection,
and only one of these couples had concordant oral–oral infection
(this couple also had genital–genital and genital-oral concordance
with this same HPV type; Table 3). Interestingly, in this couple nei-
ther partner reported ever performing oral sex. Among those with
oral HPV, men with oral HPV infection (four of six; 67%) were
more likely than women with oral HPV infection (one of four;
25%) to have a partner with concordant genital HPV infection
(p= 0.52).
At least one type-specific concordant vaginal-penile HPV infec-
tion was observed in 35% of couples (Figure 1). The proportion
with concordant vaginal-penile HPV infection varied by HIV
status as HIV-uninfected couples displayed 22% concordance,
HIV-discordant couples displayed 56% concordance, and HIV-
concordant couples displayed 100% concordant vaginal-penile
infection (p= 0.028).
RISK FACTORS FOR PREVALENT ORAL HPV INFECTION
In multivariate analysis, oral HPV prevalence was higher, although
not statistically significantly different, among HIV-positive
individuals (OR: 5.35; 95% CI 0.64–44.69), males (OR: 5.06;
95% CI 0.71–36.21), and those with ≥2 lifetime oral sex part-
ners compared to those with <2 lifetime oral sex partners (OR:
4.24; 95% CI 0.76–23.62), Table 4.
DISCUSSION
This is one of the first studies to explore oral-genital HPV con-
cordance in couples. We found that 12% of couples displayed
oral-genital concordance and among these couples the majority
had male oral HPV infection concordant with female vaginal HPV
infection. This is consistent with higher likelihood of vaginal-to-
oral transmission as compared to penile-to-oral transmission, and
may help explain previously reported findings of a lack of signif-
icant association between oral-penile contact and incident oral
HPV infections amongst women (21). Oral–oral HPV concor-
dance was rare in our study, even among HIV-infected individuals,
consistent with no or low salivary transmission.
Our study demonstrated oral HPV prevalence of 15%, con-
sistent with previous studies from South Africa, which showed an
oral HPV prevalence of 20–25% (22, 23). Risk factors for oral HPV
infection were similar to those reported in other studies, including
performing oral sex, male gender, and HIV-infection (4, 24).
Vaginal HPV was detected in >90% of females in our study
and the majority of these individuals were found to have onco-
genic HPV subtypes. Direct comparisons to previously reported
estimates of vaginal HPV amongst women in South Africa are dif-
ficult as previous studies report HPV prevalence based on degree
of dysplasia present, however population based estimates pre-
viously reported for any HPV subtype in women with normal
cytology were roughly 21% (25, 26) and ranged from 3.6 to 63%
for high-risk subtypes 16 and 18 depending on degree of dys-
plasia present (22, 25–29). Additionally, HPV prevalence amongst
HIV-positive women in South Africa approaches 80% (11). Our
overall reported vaginal HPV prevalence exceeds these previously
reported estimates, although our sample size was small. When
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FIGURE 1 | Frequency of type-specific HPV concordance, by site, among 34 couples.
Table 3 | Oral-genital concordance couple characteristics among nine couples with at least one oral HPV infection.
Couple number Oral HPV Genital HPV HIV status Ever oral sex
Male Female Male Female Male Female Male Female
1 62/72 62 62 18/52/53/62 HIV-uninfected HIV-infected No No
2 35/33/58/52 – 6/35/42/45 33/35/58/6/45 HIV-uninfected HIV-infected Yes Yes
3 16 – 16/66 16/51/66 HIV-uninfected HIV-uninfected Yes Yes
4 62/72 – – 62 HIV-uninfected HIV-uninfected Yes Yes
5 62/72 – 16/33/35 16/33/35 HIV-uninfected HIV-uninfected Yes No
6 72 – 54 16/54 HIV-uninfected HIV-uninfected Yes Yes
7 – 52/33/35/58 – 62/72 HIV-uninfected HIV-infected Yes Yes
8 – 66 52 66/82 HIV-uninfected HIV-uninfected Yes Yes
9 – 62/74 6/11/33/39/45/64/66/67/83/84 26/45/66/82/83 HIV-infected HIV-infected Yes Yes
Concordant oral-genital infections shown in red.
looking solely at oncogenic subtypes (i.e., high-risk) or HPV 16
alone, our findings appear similar (17, 18, 20).
Penile HPV was detected in 59% of males and 29% were found
to have oncogenic HPV subtypes. The prevalence of high-risk
HPV subtypes amongst males in South Africa has been previously
reported as 15% for circumcised males and 22% for uncircumcised
males (30). In our study, we did not categorize men by circumci-
sion status, and our reported prevalence is moderately higher than
these previous studies. There was a strong correlation between
HIV status and both genital HPV prevalence and genital–genital
HPV concordance between couples, which is consistent with pre-
vious studies (31). For oral HPV there was a trend toward higher
prevalence amongst HIV-positive individuals, but this finding was
not statistically significant.
While this study was cross sectional, the agreement in oral-
genital HPV infection between couples is consistent with trans-
mission by oral sex. Additionally, in three out of the four couples
with concordant oral-genital HPV infection, the partner with
oral HPV reported having performed oral sex, a finding consis-
tent with previous reports of an association between oral HPV
prevalence and reported oral sex (32). The remaining couple dis-
played both oral–oral and oral-genital HPV concordance, but
reported no oral sex. Possible modes of transmission in this couple
could include deep kissing or auto-inoculation, as both of these
modes of transmission have previously been suggested, although
not clearly demonstrated (33, 34). However, oral–oral HPV con-
cordance was low suggesting HPV may not be transmitted by
deep kissing, or may be rare. It is noteworthy that oral-genital
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Table 4 | Unadjusted and adjusted odds ratios of oral HPV infection
(n=68).
Unadjusted
OR
95% CI Adjusted
OR
95% CI
Age (per 5 years) 1.66 0.91–3.03 2.24 0.94–5.35
HIV STATUS
HIV-uninfected 1.00 1.00 1.00 1.00
HIV-infected 2.06 0.45–9.35 5.35 0.64–44.69
GENDER
Female 1.00 1.00 1.00 1.00
Male 1.61 0.41–6.30 5.06 0.71–36.21
NUMBER OF ORAL SEX PARTNERS
<2 Lifetime oral
sex partners
1.00 1.00 1.00 1.00
≥2 Lifetime oral
sex partners
5.22 1.01–26.95 4.24 0.76–23.62
concordance was substantially lower than genital–genital concor-
dance, this could be because oral sex is less frequent than vaginal
sex and/or because per-act transmissibility could be different for
oral vs. genital sex.
This study had several limitations. The small sample size lim-
ited the analysis of risk factors for infection. Because data was
collected in categories exact medians could not be recorded. Addi-
tionally, our study provides cross-sectional data only so could
not demonstrate transmission over time from one partner to
another. However this study provides some of the first estimates
of oral–oral and oral-genital HPV concordance in couples in
Africa.
This research demonstrates high prevalence of genital HPV
infection and moderate prevalence of oral HPV infection in a
South African population with a modest number of sexual part-
ners. The HPV vaccine has recently been shown to be effective in
preventing oral, as well as cervical and anal HPV infection (35),and
this data underscores the importance of preventative HPV vacci-
nation in South Africa. The concordant oral-genital HPV infection
detected in these couples supports the transmission of HPV infec-
tion to the mouth by oral sex. Given higher HPV prevalence,
persistence, and HPV-associated cancer risk among HIV-infected
individuals (8), the prevalence of oncogenic oral HPV infection in
this population is of note. HPV-associated oropharyngeal cancer
incidence has increased in the U.S. and some European countries
over the past several decades (3). Given the high HIV prevalence
in South Africa and other countries in the region, as individuals
with HIV live longer due to effective ART, it is not known whether
a similar increase in HPV-associated oropharyngeal cancer will be
observed in this region.
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